Therapies targeting the transforming growth factor‐β (TGF‐β) superfamily, which are negative regulators of erythroid progenitor differentiation, are currently being investigated in the trial setting and are showing promise in ameliorating MF‐associated anaemia. This evidence concerns the gene TGFB1 and anemia (phenotype).